SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Jack London

PatientJack London
Date of birth1987-01-12
IdentifiersMRN HR-ET010-SYN; SSN (made up) 000-10-4482
Document date2026-08-18
AuthorEleanor Whitcombe-Ibe, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review after stopping alcohol and starting losartan, seen the same day by nephrology. [S]

History of Present Illness

Mr. London stopped drinking on the morning after his intake visit and took the five-day chlordiazepoxide taper as prescribed, with a daily telephone check from the nurse. The first three days brought sweats, a tremor and poor sleep, at worst a CIWA-Ar of 11 on the second day, with no hallucinations or seizures; by the fifth day the tremor had gone, and he has had no alcohol since. He missed two mornings of writing and has written his thousand words every other day. He has taken losartan 50 mg daily without dizziness and stopped naproxen; acetaminophen eases his knee. His ankles are less swollen. He has seen the clinic's addiction counselor once. The insurance examination report has arrived, confirming a creatinine of 1.7 mg/dL about fourteen months ago. Ultrasound and liver elastography were done this morning. He sees Dr. Mbatha-Rasmussen of nephrology this afternoon. [S]

ElementDetail
AlcoholNone for twelve days; withdrawal completed, peak CIWA-Ar 11
Losartan50 mg daily for two weeks; no side effects
Potassium and creatinine4.9 mmol/L; 2.04 mg/dL (eGFR 42), up 3 percent
Earlier creatinine1.7 mg/dL about fourteen months ago
UltrasoundKidneys normal in size, echogenic, no stones or obstruction; fatty liver
ElastographyLiver stiffness 7.2 kPa

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired, but sleeping better than last week
CardiovascularPositiveAnkle swelling less
GenitourinaryNegativeNo flank pain or blood in the urine
NeurologicalNegativeTremor gone; no confusion
PsychiatricPositiveRestless and irritable; no thoughts of self-harm

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Naproxen 500 mg oral tablet twice daily, bought over the counter at full strength and taken most days for about two years for knee and back pain; stopped at intakeOne tablet by mouth twice a day, self-directedOral route2024-08-01 to 2026-08-04stoppedS
Losartan 50 mg oral tablet once dailyOne tablet by mouth every morningOral route2026-08-04 to 2026-09-15completedS
Chlordiazepoxide 25 mg oral capsule, fixed five-day taper for alcohol withdrawal (four capsules on day 1, three on day 2, two on day 3, one on days 4 and 5), dispensed for five days only, with a daily telephone checkUp to one capsule four times a day on day 1, tapering to one a day by day 4; stop after day 5; no alcohol or drivingOral route2026-08-04 to 2026-08-08completedS
Thiamine 100 mg oral tablet once dailyOne tablet by mouth dailyOral route2026-08-04activeS
Acetaminophen 500 mg oral tablet, one or two tablets up to four times a day as needed for pain, no more than 2,000 mg in a day, in place of naproxenOne to two tablets by mouth every six hours as needed; no more than four tablets a dayOral route2026-08-04activeS
Naltrexone 50 mg oral tablet once daily, with a wallet card warning that it blocks opioid pain medicinesOne tablet by mouth every morningOral route2026-08-18activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-08-18Body height173cmS
2026-08-18Body weight83.6kgS
2026-08-18Body mass index (BMI) [Ratio]27.9kg/m2S
2026-08-18Systolic blood pressure146mm[Hg]S
2026-08-18Diastolic blood pressure92mm[Hg]S
2026-08-18Heart rate84/minS
2026-08-18Respiratory rate16/minS
2026-08-18Body temperature36.6CelS
2026-08-18Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-08-18Potassium [Moles/volume] in Serum or Plasma4.9mmol/L3.5-5.1 mmol/LNormalS
2026-08-18Creatinine [Mass/volume] in Serum or Plasma2.04mg/dL0.74-1.35 mg/dLHighS
2026-08-18Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M42mL/min/{1.73_m2}45 to 59 is G3a; 30 to 44 is G3bLowS
2026-08-18Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma49U/L10-40 U/LHighS
2026-08-18Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma36U/L9-46 U/LNormalS
2026-08-18Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma141U/L8-61 U/LHighS

Physical Exam

Vital signs recorded on 2026-08-18; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 146/92, pulse 84; weight 83.6 kg
CardiovascularRegular rhythm; no murmur; trace ankle edema
NeurologicalNo tremor; gait normal
PsychiatricCalm and engaged; no thoughts of suicide

Problems

ProblemClinical statusVerificationCodeProvenance
Tiredness, ankle swelling and high blood pressure (158/98 mmHg) with a raised creatinine (1.98 mg/dL, eGFR 43) and albumin in the urine (240 mg/g), found at intake; a creatinine of 1.7 mg/dL at an insurance examination about fourteen months ago, by his account; chronicity and cause under evaluation with a nephrology consultationresolvedconfirmed R94.4S — Synthetic presenting problem anchored to the documented kidney damage found in 1913; superseded when the consultation staged chronic kidney disease.
Chronic kidney disease, stage G3b A2 (eGFR 42 to 43, urine albumin 240 mg/g), most likely from hypertension with a contribution from two years of daily naproxen; kidneys of normal size, without stones or obstruction; urine sediment bland; synthetic modern diagnosis linked to his documented kidney diseaseactiveconfirmed N18.32S — Synthetic modern diagnosis made at the consultation, anchored to his documented kidney damage and death from uraemia; the cause in the modern episode is synthetic and is not a claim about his real kidneys.
Hypertensive chronic kidney disease, untreated until intakeactiveconfirmed I12.9S — Synthetic modern diagnosis made at the consultation.
Alcohol use disorder, severe (seven DSM-5-TR criteria): a bottle of whisky or more most days for years, a morning drink to steady his hands, failed attempts to cut down, and drinking despite knowing it harms his health; AUDIT 27; PEth 410 ng/mLactiveconfirmed F10.20S — Synthetic modern diagnosis anchored to his own published account of heavy drinking; the criteria, scores and amounts are synthetic and are not a claim about his real drinking.
Alcohol-associated fatty liver without advanced fibrosis (liver stiffness 7.2 kPa; steatosis on ultrasound); FIB-4 2.28 at intakeactiveconfirmed K70.0S — Synthetic finding of the ultrasound and elastography at the consultation; not a claim about his real liver.
Daily self-directed naproxen for knee and back pain for about two years, stopped at intake; acetaminophen in its placeresolvedconfirmed Z79.1S — Synthetic medication history; the joint pain is anchored to the documented rheumatism of 1914, which is not given a diagnosis.
Cigarette smoking, about ten a day; not ready to stop while he stops drinkingactiveconfirmed F17.210S — Synthetic tobacco use; a physician-author's suggestion of heavy tobacco use is recorded only as a retrospective claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationStandardized office blood pressure (five minutes' rest, validated device, average of readings)Every visitCompleted today146/92 mmHg
LaboratoryPotassium and creatinine after starting or changing losartan or an SGLT2 inhibitorTwo to four weeks after each start or changeCompleted todayTwo weeks after losartan 50 mg: potassium 4.9 mmol/L; creatinine 2.04 mg/dL, up 3 percent; eGFR 42
LaboratoryCreatinine with eGFR and urine albumin-to-creatinine ratioG3b A2: twice a year, and at each medicine checkUp to dateeGFR 43 and urine albumin 240 mg/g at intake; with a creatinine of 1.7 mg/dL fourteen months ago, chronic for more than three months
LaboratoryUrinalysis with microscopyAt diagnosisUp to dateBland at intake: 2+ protein, no blood, casts or crystals
ImagingKidney ultrasoundAt diagnosis of chronic kidney disease of unclear causeCompleted todayKidneys 10.8 and 11.0 cm, echogenic, no stones or obstruction
LaboratoryCalcium, phosphate and PTHG3a to G3b: every six to twelve monthsUp to dateCalcium 9.2 and phosphate 3.8 mg/dL; PTH 74 pg/mL, mildly high, at intake
Laboratory25-hydroxyvitamin DAt baselineDeferredThe baseline 25-hydroxyvitamin D was left off the intake order and was not drawn. PTH is only mildly high and calcium and phosphate are normal, so no harm is likely from a delay of a few weeks. Corrective action: added to the next blood draw, and the clinic's new-CKD order set checked
LaboratoryHemoglobinG3: at least yearlyUp to date13.6 g/dL at intake
LaboratoryLipid panelOnce at diagnosisUp to dateLDL 128 mg/dL at intake; statin not indicated at 39
SurveyKidney failure risk equation (2- and 5-year)Yearly in G3 to G5, and before referral decisionsCompleted todayFive-year risk about 5 percent; two-year about 1.5 percent
Medication safetyMedication reconciliation: no NSAIDs, kidney dosing, contrast safetyEvery visitCompleted todayNaproxen stopped; acetaminophen within 2,000 mg a day
Self-managementLifestyle: sodium below 2 g a day, activity, diet, weightEvery visitCompleted todaySodium below 2 g a day explained; protein about 0.8 g/kg
SurveyDrinking since the last visit (self-report)Every visitCompleted todayNone for twelve days
Medication safetyWithdrawal monitoring (CIWA-Ar) and thiamineDuring withdrawal; thiamine throughout early recoveryCompleted todayWithdrawal completed with a peak CIWA-Ar of 11 on day 2; no seizures or hallucinations; thiamine continued
LaboratoryLiver tests (AST, ALT, GGT) on naltrexoneAt baseline, at four to six weeks, then every few monthsCompleted todayBefore naltrexone: AST 49, ALT 36, GGT 141 U/L, falling
Medication safetyNaltrexone safety: opioid use, nausea, wallet cardAt the start and every visitCompleted todayNo opioid use; wallet card given; started today
ImagingLiver fibrosis: FIB-4, then elastography if indeterminateAt diagnosis of alcohol-associated liver diseaseCompleted todayFIB-4 2.28 at intake; liver stiffness 7.2 kPa today
ReferralNephrology consultationAt diagnosis, with a five-year kidney failure risk of 3 to 5 percent or moreCompleted todaySeen by Dr. Mbatha-Rasmussen today
ReferralAddiction-focused counseling and mutual helpWeekly in early recoveryCompleted todayFirst session done; weekly from now
SurveySuicide-risk review, firearms storage, safety plan and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; firearms locked with the ammunition apart; 988 card carried
Self-managementTobacco use and readiness to stopEvery visitCompleted todayAbout ten a day; not ready to stop

Goal progress:

Guideline basis: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026); The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)

Follow-up: Six-week review with potassium, creatinine, urine albumin, liver tests, PEth and vitamin D. Counseling weekly. The clinic or 988 at any hour. Next scheduled visit 2026-09-15: six-week review: drinking and PEth, blood pressure, potassium and creatinine, urine albumin, liver tests, mood and safety. [S]